Mast cells (MCs) are key effector cells in the elicitation of IgE-mediated allergic responses. Close physical proximity between T cells and MCs and activation of the latter have been demonstrated in several T cell-mediated inflammatory processes and have led investigators to propose a bidirectional interaction between these 2 cell populations. [1] [2] [3] [4] However, the molecular mechanism by which MCs are activated in these conditions remains elusive. Previously, we have reported that direct physical contact between MCs and activated T lymphocytes or their membranes is associated with Ras activation and sustained extracellular signal-regulated kinase (ERK) phosphorylation that results in MC activation and mediator release. [5] [6] [7] [8] Furthermore, MCs could also be stimulated by microvesicles released from activated T cells, thereby promoting a response in the absence of direct physical contact with T cells at the site of inflammation. 9 These T cell-derived microvesicles are actively internalized into MCs, a process that can be detected as early as 1 hour after initiation and requires 24 hours for completion, culminating in both degranulation and cytokine release. 10 In the present study we aimed to further uncover the mechanism by which T cell-derived microvesicles affect MC activation.
In addition to sharing surface markers of their parental cells, microvesicles carry a broad variety of cytoplasmic components, including proteins, DNA, and RNA. 11 These microvesicles might act as intercellular carriers and might deliver bioactive proteins and RNA to recipient cells, including mRNAs 12 and microRNAs (miRs), 13, 14 which can affect their properties. miRs are a large class of small noncoding regulatory molecules (19) (20) (21) (22) (23) (24) nucleotides) that regulate genes expression by binding directly to the 39-untranslated region (UTR) of specific mRNA target, leading to reduction of protein synthesis by means of repression of translation or by inducing mRNA degradation. 15 The ability of microvesicles to contain and transfer miRs to recipient cells prompted us to investigate whether and which miRs might be involved in activation of microvesicles derived from activated T cells (mvT*)-induced MCs.
Here we demonstrate that stimulation of MCs with mvT*s leads to overexpression of miR-4443, which has not been recognized thus far in MCs. MiR-4443 served as a negative regulator of the protein tyrosine phosphatase receptor type J (PTPRJ) gene, which is known to modulate the Ras-signaling pathway through dephosphorylation of ERK. 16 Furthermore, overexpression of miR-4443 was found to regulate ERK phosphorylation and IL-8 release in MCs activated by mvT*s. Thus, by delivering miR-4443, T cell-derived microvesicles can play an important role in MC activation within T cell-mediated inflammatory processes in which MCs were found to be involved.
METHODS

Antibodies and reagents
The following antibodies were used for this study: anti-PTPRJ (R&D Systems, Minneapolis, Minn), anti-tubulin (Sigma-Aldrich, St Louis, Mo), anti-phospho-ERK (Cell Signaling Technology, Danvers, Mass), and horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, Pa). The RNA polymerase inhibitor a-amanitin was purchased from Sigma-Aldrich.
Cell culture
Reagents for cell culture were purchased from Biological Industries (Beit Haemek, Israel). Jurkat T-cell leukemia cells were maintained in RPMI 1640 supplemented with 10% FCS, 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 12.5 U/mL nystatin. The human LAD2 MCs were maintained in StemPro-34 SFM (GIBCO Invitrogen Corporation, Grand Island, NY) supplemented with 2 mmol/L L-glutamine, 50 mg/mL streptomycin, 100 IU/mL penicillin, and 100 ng/mL recombinant human stem cell factor (SCF; PeproTech, Rocky Hill, NJ), as previously described. 17 Cell activation LAD2 MCs were activated by means of incubation with 50 mg/mL purified microvesicles derived from resting T cells (mvTs) or activated T cells (mvT*s), as previously described. 9 For IgE-mediated activation, cells were sensitized overnight with 500 ng/mL human myeloma IgE (Calbiochem, Merck KGaA, Darmstadt, Germany) and then stimulated with 10 mg/mL anti-human IgE (Dako, Glostrup, Denmark). Primary cultured human cord blood mast cells (CBMCs) were derived from human cord blood mononuclear cells in the presence of SCF, IL-6, and prostaglandin E 2 and used as previously described. 8 Jurkat T cells were activated with 75 ng/mL phorbol 12-myristate 13-acetate (PMA) (Calbiochem) for 1 hour, followed by extensive washes, as previously described. 8 Human peripheral blood-derived T lymphocytes were activated by anti-CD3/anti-CD28 antibodies, as previously described. 9 
RNA isolation
The experimental protocol is detailed in the Method section in this article's Online Repository.
NanoString technology
miRNA (miR) expression profiling of LAD2 cells activated with mvTs or mvT*s or left untreated was performed with the human V1 miRNA assay kit (NanoString Technologies, Seattle, Wash), as previously reported. 18 Real-time PCR for miRs miR-4443 was quantified by using the qScript miRNA cDNA synthesis kit, followed by real-time PCR analysis with PerfeCta miRNA assays and PerfeCta SYBR Green master mix (Quanta Biosciences, Gaithersburg, Md). The small nuclear RNA RNU44 was used as reference for gene quantitation.
Real-time PCR
cDNA was synthesized by using the high-capacity cDNA reverse transcriptase kit (Applied Biosystems, Carlsbad, Calif). Gene expression was determined by means of Fast Real-Time PCR with an ABI 7500 Thermal Cycler (Applied Biosystems). Expression of the gene PTPRJ was measured by using specific TaqMan probes (human-PTPRJ NM_002843, Applied Biosystems). b-Glucuronidase gene (GUSB) was used as a housekeeping gene for analysis of changes in cycle threshold values.
Transfection of LAD2 cells miR-4443 mimic, mimic negative control, miR-4443 inhibitor, or inhibitor negative control (50 nmol/L; miRVana, Applied Biosystems) were transfected into LAD2 cells by using the TransIT-X2 Dynamic Delivery System (Mirus, Madison, Wis), according to the manufacturer's instructions, in LAD2 medium (StemPro-34) without addition of StemPro nutrient supplement and antibiotics for 4 hours at 378C. At the end of the incubation period, StemPro-34 medium with nutrient supplement, 100 ng/mL SCF, and antibiotics was added, and the cells were incubated at 378C for an additional 24 to 48 hours.
cDNA expression plasmids (5 mg) were transfected into LAD2 cells with DMRIE-C reagent (Invitrogen, Grand Island, NY), according to the manufacturer's instructions.
Luciferase assay
LAD2 cells were cotransected with 0.5 mg of pLightSwitch PTPRJ-39-UTR plasmid or pLightSwitch reporter gene plasmid (Active Motive, Carlsbad, Calif) and 50 nmol/L miR-4443 mimic or mimic negative control in a 96-well plate by using DMRIE-C Reagent (Invitrogen), according to the manufacturer's instructions. After 24 hours, luciferase activity was measured with the pLightSwitch Luciferase Assay kit (Switchgear; Genomics, Carlsbad, Calif), according to the manufacturer's protocol.
SDS-PAGE and immunoblotting
Cellular extracts were separated by using SDS-PAGE with 7.5% to 10% polyacrylamide gels, transferred to polyvinylidene difluoride filters, and processed for immunoblotting, as previously described. 7 Immunoreactive bands were visualized with the LAS-3000 Imaging System (Fujifilm, Tokyo, Japan).
Statistical analysis
Results are presented as means 6 SEMs. Statistical analysis was performed by using the unpaired Student t test. A P value of less than .05 was considered statistically significant.
The experimental protocols for cDNA constructs, isolation of microvesicles, human cytokine assay, and microarray experiment and data analysis are detailed in the Methods section in this article's Online Repository at www.jacionline.org.
RESULTS
PTPRJ levels decrease in mvT*-activated MCs
As previously reported, microvesicles derived from activated (mvT*s) but not from resting (mvTs) T cells are internalized into MCs, leading to degranulation and cytokine release. 9, 10 These events result in Ras activation and sustained ERK phosphorylation. 6, 7 To further decipher the effect of mvT*s on MC function, we examined the global gene expression profiles induced by (Fig 1, D) were incubated with mvTs or mvT*s (Fig 1, A and C) or activated by FcεRI cross-linking (Fig 1, B) . PTPRJ mRNA levels were analyzed by using qRT-PCR and normalized to the levels of GUSB. Data are relative to untreated cells. E and F, PTPRJ protein levels were assessed by using Western blot analysis (Fig 1, E) and quantitated by using densitometric analysis (Fig 1, F) . Results are shown from 3 independent experiments (means 6 SEMs). *P < .05 and **P < .01.
incubating MCs with either mvTs or mvT*s. Microarray analysis disclosed a significant downregulation (23.129-fold change, P < .05) of the transmembrane receptor protein tyrosine phosphatase PTPRJ gene (also known as CD148 or DEP-1) after stimulation of MCs with mvT*s (data not shown). Importantly, PTPRJ has previously been shown to act as an inhibitor of the Ras pathway by directly dephosphorylating phosphorylated ERK. 16 These results were validated by using quantitative real-time PCR (qRT-PCR; Fig 1, A-D) and Western blot analysis (Fig 1,   E and F) . Indeed, downregulation of PTPRJ mRNA levels could be demonstrated after incubation of MCs with mvT*s for 4 and 24 hours (Fig 1, A) . Moreover, dose-response analysis with increased concentrations of mvT*s revealed maximal decrease of PTPRJ mRNA levels with 50 mg/mL mvT*s (Fig 1, C) . In contrast, IgE-mediated activation (FcεRI cross-linking) of LAD2 MCs had no effect on PTPRJ mRNA expression (Fig 1,  B) . Decreased expression of PTPRJ mRNA was also detected after addition of mvT*s for 24 hours to mature (9 to 10 weeks old) human cord blood-derived MC cultures (CBMCs ; Fig 1, D) , thus (Fig 2, B and C) or CBMCs (Fig 2, D) were incubated as indicated, and miR-4443 levels were measured by using qRT-PCR and normalized to RNU44 levels. Data are relative to untreated cells. E, Resting or phorbol 12-myristate 13-acetate (PMA)-activated Jurkat T cells or their microvesicles were analyzed for their miR-4443 content by using qRT-PCR. F, LAD2 cells were incubated with mvT*s in the presence of 50 mg/mL a-amanitin, and the selected miRs were evaluated by using qRT-PCR. Results are shown from 3 independent experiments (means 6 SEMs). *P < .05 and **P < .01.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 supporting the validity of LAD2 as a human MC model. Furthermore, PTPRJ protein levels were also decreased after incubation of MCs for 4 and 24 hours with mvT*s but not with IgE plus antigen (Fig 1, E and F) . These results indicate that both mRNA and protein levels of PTPRJ are downregulated on specific activation of MCs by mvT*s.
miR expression in mvT*-induced MC activation
We hypothesized that the decrease in PTPRJ expression might be attributed to miRs carried by microvesicles. To this end, we examined the global miR gene expression profiles induced by incubation of LAD2 cells with either mvTs or mvT*s by using NanoString technology 18 or qRT-PCR. After stimulation of MCs with mvT*s but not mvTs, microarray analysis disclosed a significant upregulation of 6 miR genes (fold change cutoff, 2.0; see Fig E1 in this article's Online Repository at www.jacionline. org). Among the transcripts, the miR-4443 gene was of particular interest because of strong induction in LAD2 human MCs (fold change, 5; Fig 2, A) . Furthermore, the expression of this miR has not been reported in human MCs. qRT-PCR has validated these findings. As shown in Fig 2, B, the miR-4443 level was indeed increased in MCs activated with mvT*s but not with mvTs or IgE plus antigen. The increase in the expression of miR-4443 was first noticed after 6 hours and peaked after activation of the cells for 24 hours (see Fig E2 in this article's Online Repository at www.jacionline.org), consisting of our previous results demonstrating that mvT*s are actively internalized into the cells after a 24-hour incubation period.
10 Dose-response analysis revealed maximal miR-4443 expression with 100 mg/mL mvT*s (Fig 2, C) . Experiments with mature human CBMCs demonstrated a marked increase in miR-4443 levels in response to activation of primary MC cultures with mvT*s but not mvTs (Fig 2, D) . Of note, microvesicles isolated from peripheral blood T cells and activated by anti-CD3/anti-CD28 antibody-coated beads were also found to induce high levels of miR-4443 in LAD2 cells (see Fig E3 in this article' s Online Repository at www.jacionline.org).
Microvesicles are known to contain and transfer miRs to other cells.
11-14 Therefore qRT-PCR was used to determine the presence of miR-4443 in either T cells or microvesicles derived from activated or resting Jurkat T cells. As shown in Fig 2, 
LAD2 MCs were treated with a-amanitin, a specific inhibitor of RNA polymerase II, before microvesicle treatment to ensure that the target cells did not upregulate the expression of miR-4443 on microvesicle treatment. 19 As shown in Fig 2, F , similar miR-4443 expression was detected in the microvesicle-treated cells, regardless of the presence of a-amanitin, whereas other miRs, which were found to be upregulated by mvT*s, were significantly decreased. Of note, a-amanitin did not change the cycle threshold values of RNU44 that served as reference for gene quantitation. Thus miR-4443 is indeed present in mvT*s that in turn deliver it into MCs.
miR-4443 regulates PTPRJ gene expression and function
Next, we searched for evidence that miR-4443 might actually regulate PTPRJ expression. This hypothesis was supported by a recent report that an miR accounts for enhanced IL-4 production by MCs through targeting a specific phosphatase. 20 For this purpose, we used microRNA target filter databases, such as TargetScan (www.tragetscan.org), which are able to predict target genes of specific miRs based on 39-UTR complementary sequences. This bioinformatics analysis revealed that the PTPRJ gene has a critically conserved binding site for miR-4443, indicating that miR-4443 might interact directly with the 39-UTR of this gene. Therefore we conducted a luciferase reporter assay to monitor miR-4443 binding to the 39-UTR of the PTPRJ gene. LAD2 cells were cotransfected with reporter plasmid containing the full length of the PTPRJ-39-UTR downstream of the firefly luciferase coding sequence together with miR-4443 mimic. The results showed that the luciferase activity of cells transfected with the miR-4443 overexpression vector was significantly decreased (80% decrease) compared with that in cells transfected with the blank vector control (mimic NC group), demonstrating that PTPRJ was inhibited by binding of miR-4443 to its 39-UTR (Fig 3) .
To further verify that PTPRJ is a functional target gene of miR-4443, LAD2 cells were transfected with either miR-4443 mimic or its negative control, followed by activation of the cells with mvT*s. Overexpression of miR-4443 in resting cells, but not its negative control, led to a decrease in PTPRJ mRNA expression (Fig 4, A) . The very same effect was noticed in cells that were exposed to microvesicles, with an approximately 50% decrease in PTPRJ expression in those activated by mvT*s (Fig 4, B) . On the other hand, overexpression of miR-146a, which was also found to be upregulated in response to activation of the cells with mvT*s, did not affect PTPRJ expression (data not shown). In contrast, transfection with miR-4443 inhibitor increased PTPRJ mRNA expression by approximately 40% (Fig 4, C) . Overexpression of miR-4443 mimic also led to a decrease in PTPRJ protein levels after activation of LAD2 cells with mvT*s (Fig 4, D and E) . These results indicate that miR-4443 functionally regulates PTPRJ at both the mRNA and protein levels.
miR-4443 regulates ERK phosphorylation
Recently, we reported that stimulation of MCs by mvT*s is associated with Ras activation and sustained ERK phosphorylation. 6, 7 As reported previously, the phosphatase PTPRJ modulates Ras downstream effectors by directly dephosphorylating Tyr-204 of ERK. 16 Thus we hypothesized that the miR-4443-induced decrease in PTPRJ expression might affect ERK phosphorylation and function. LAD2 cells were transfected with miR-4443 mimic or inhibitor, followed by stimulation of the cells with mvT*s, to investigate the effect of miR-4443 on ERK, and the level of phosphorylated ERK was Fig 4, A and B) , or 30 nmol/L miR-4443 inhibitor or NC inhibitor (Fig 4, C) for 24 hours. Then the transfected cells were activated with mvTs or mvT*s for 24 hours (Fig 4, B and C) . PTPRJ mRNA levels were measured by using qRT-PCR and normalized to levels of GUSB. Data are compared with mimic/inhibitor-NC-transfected cells. D, The PTPRJ protein level was measured by using Western blot analysis and was normalized to a-tubulin. This is a representative experiment of 3 different experiments. E, Densitometry presented as a percentage of mimic NC response. *P < .05 and **P < .01.
recorded by using Western blotting. As shown in Fig 5, A and B , enhanced ERK phosphorylation was observed in miR-4443-overexpressing cells, and transfection with the miR-4443 inhibitor reduced the phosphorylated ERK levels.
In contrast, overexpression of the PTPRJ gene by using PTPRJ expression plasmid followed by stimulation with mvT*s for 24 hours resulted in a modest but significant decrease (approximately 20%) in ERK phosphorylation (Fig 5, C and D) , indicating that miR-4443 retains MC activity in the presence of ''normal'' PTPRJ levels.
miR-4443 regulates IL-8 release
Previously, it has been shown that sustained ERK phosphorylation in MCs activated by T cells leads to IL-8 release.
7 Therefore the effect of miR-4443 on cytokine release by mvT*-activated MCs was investigated. miR-4443 mimic or inhibitor was overexpressed in MCs, followed by stimulation with mvT*s. IL-8 release was then detected by using ELISA. As shown in Fig 6, A, when LAD2 cells were transfected with the miR-4443 mimic, a significant increase of approximately 50% in IL-8 release was detected, whereas overexpression of Thereafter, cells were stimulated with mvT*s for 24 hours. A, Levels of phosphorylated ERK (pERK) and a-tubulin were analyzed by using Western blotting. B, Densitometry from 1 representative experiment of relative bands of phospho-ERK presented as a percentage of mimic or inhibitor negative control (NC) response. C, LAD2 cells were transfected with 5 mg of PTPRJ expression plasmid or with the empty vector phosphorylated enhanced green fluorescent protein as a control for 48 hours, followed by activation with mvT*s for 24 hours. Levels of phosphorylated ERK, PTPRJ, and a-tubulin were analyzed by means of Western blotting. This is a representative experiment of 2 different experiments. D, Densitometry presented as a percentage of LAD2 cells with mvT*s. Results are shown from 2 independent experiments (means 6 SEMs). *P < .05 and **P < .01.
the miR-4443 inhibitor resulted in decreased IL-8 release (Fig 6,  B) . These results indicate that miR-4443 is involved in IL-8 release from mvT*-treated MCs, probably by downregulating PTPRJ.
In summary, these results are consistent with the scenario by which activated T cells might deliver, through microvesicle release, miR-4443 to MCs, which regulates PTPRJ gene expression. Downregulation of PTPRJ leads to increased ERK phosphorylation and augmented release of cytokines, such as IL-8, from mvT*-treated MCs (Fig 7) .
DISCUSSION
Recent studies have shown that MC degranulation and cytokine production can be induced by heterotypic adhesion to activated, but not resting, T cells. [5] [6] [7] [8] Previously, we postulated that activation of MCs after contact with T cells or their microvesicles might induce an expression profile that would be different from stimulation by ''classical'' IgE receptor cross-linking. 3, 5, 8, 10 This unique activation pathway leads to sustained ERK activation 7 and release of specific cytokines, such as IL-24, IL-8, and oncostatin M. [8] [9] [10] However, the mechanism underlying the stimulation of MCs by microvesicles remains unknown.
In the present study we sought to discover factors that mediate the effect of mvT*s on MC function. We now show that activation of MCs with mvT*s, but not by FcεRI cross-linking, leads to downregulation of PTPRJ, a ubiquitous receptor-type protein tyrosine phosphatase that modulates the Ras pathway through dephosphorylation of ERK. 16 PTPRJ is a widely expressed transmembrane protein that plays a role in multiple signaling pathways. 21 Substrates of PTPRJ include proteins that belong to a family of kinase receptors, such as epidermal growth factor receptor, platelet-derived growth factor, and vascular endothelial growth factor receptor. [22] [23] [24] Several studies have addressed the role of PTPRJ in regulating cellular pathways, underling the role of PTPRJ as a negative regulator of cell proliferation and function. 21, 22 A previous finding of ERK activation and downregulation of PTPRJ in response to activation of MCs with mvT*s (Fig 1) prompted us to hypothesize that the decrease in PTPRJ expression can be attributed to miRs carried by microvesicles. Significant evidence has been accumulated showing that microvesicles released from various cell types can transfer miRs to neighboring or distant cells in which these exogenous miRs function similarly to endogenous miRs in regulating target gene expression and recipient cell function. 25, 26 For instance, platelets activated by thrombin deliver miR-223 through microvesicles to human umbilical vein endothelial cells, leading to accumulation of platelet-derived miR-223 in the latter. 13 Also, monocyte-derived microvesicles are able to transfer miR-150 to endothelial cells and promote angiogenesis. 27 In the present study we performed global screening of miR expression in MCs activated with mvT*s by using NanoString technology. One of the miRs that was specifically expressed at significant levels was miR-4443 (Fig 2) . miR-4443 was of particular interest for several reasons: it showed a very strong induction in LAD2 human MCs, its expression was not documented heretofore in human MCs, and it was found to be present in glioma microvesicles. 28 miR-4443 levels were increased after a relatively long period of 24 hours of MC activation, although less so after a shorter period of 4 hours. Furthermore, activated T cells or their microvesicles were also found to express this miR, whereas pretreatment with a-amanitin ruled out the possibility of transcriptional activation and de novo expression of miR-4443 by LAD2 cells on microvesicle treatment (Fig 2) . These findings and the time sequence that paralleled the kinetics found with internalization of microvesicles to human MCs 10 indicate that miR-4443 was transferred to MCs through mvT*s. An earlier decrease in PTPRJ expression might be attributed to other mechanisms yet to be determined. miRs function by directly binding to the 39-UTR of specific target mRNA, leading to repression of protein expression and promotion of target mRNA degradation. 29 Because of very short complementarity to the target mRNA, a particular miR can have hundreds of target genes, and therefore collectively, miRs have been suggested to influence the expression of approximately 30% of genes. Moreover, a given target might be regulated by multiple miRs. 30 For instance, another miR, namely miR-328, was found to downregulate PTPRJ expression in HeLa and SKBr3 cells by targeting directly the 39-UTR of this gene, resulting in its decreased expression. 31 In the present study we show, by using the 39-UTR luciferase reporter assay, that miR-4443 interacts directly with the 39-UTR of PTPRJ gene as well (Fig 3) and therefore can serve as a target for this miR. Indeed, overexpression of miR-4443 by mimic molecule resulted in reduction of PTPRJ mRNA and protein levels, whereas miR-4443 inhibitor enhanced them (Fig 4) .
FcεRI-mediated ERK activity is important for cytokine production by MCs. 32 Recently, we have reported that stimulation of MCs by mvT*s is associated with Ras activation, ERK phosphorylation, and preferential IL-8 release, whereas activation of MCs by FcεRI cross-linking was followed by transient ERK activation and preferential secretion of TNF-a. 6, 7, 9 Because the phosphatase PTPRJ was found to modulate the Ras pathway by directly dephosphorylating ERK, 16 and in accordance with our previous findings, we investigated the effect of miR-4443 on ERK activation and IL-8 release. Indeed, overexpression of miR-4443 in MCs activated with mvT*s resulted in increased ERK phosphorylation and IL-8 release, whereas overexpression of the miR inhibitor decreased both ERK phosphorylation and IL-8 release (Figs 5 and 6 ). Furthermore, overexpression of PTPRJ rescued the effect of miR-4443 on ERK phosphorylation (Fig 5) , indicating the interrelationship between the miR-PTPRJ-phosphorylated ERK. The ability of miRs to regulate ERK activation and cytokine production was also demonstrated in bone marrow-derived MCs activated by cross-linking of FcεRI. Overexpression of miR-126 in these cells suppressed Spred1 (Sprouty-related Ena/VASP homology-1 domain-containing protein) expression and enhanced ERK activity that was associated with increased FcεRI-mediated cytokine production. 33 Also, IL-10-mediated enhanced MC function has been reported recently to be mediated through miR-155, which targeted suppressor of cytokine signaling 1. 34 Relevant to our observation, regulation of phosphatase by miRs has been documented in murine MCs stimulated with LPS. Overexpression of miR-221 was found to decrease expression of the phosphatase and tensin homolog, resulting in enhanced IL-4 secretion. 20 In summary, the observations reported herein and summarized in the model presented in Fig 7 suggest that stimulation of MCs by mvT*s results in overexpression of miR-4443, which is carried and transferred to the cells by these mvT*s. miR-4443, which serves as a PTPRJ-negative regulator, downregulates PTPRJ gene expression. This results in increased/prolonged ERK phosphorylation and IL-8 release. Thus, by delivering miR-4443, T cell-derived microvesicles might play an important role in MC activation within T cell-mediated inflammatory processes in which MCs are found to be involved. . miR-4443 levels were measured by using RT-PCR and normalized to RNU44 levels. Data are relative untreated cells. Results are shown from 3 independent experiments (means 6 SEMs). **P < .01.
